End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 MYR | 0.00% | +1.52% | -1.11% |
03-12 | Malaysian Stocks Maintain Four-Day Winning Streak; Kobay Technology's Shares Rally 12% | MT |
02-07 | Hartalega Sets Up Share Grant Scheme | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 149.5 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.79 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.11% | 1.91B | B | ||
+11.84% | 27.79B | B+ | ||
-31.93% | 2.98B | B- | ||
-15.97% | 2.52B | C+ | ||
+11.90% | 2.34B | - | A- | |
-7.78% | 1.39B | B | ||
-0.38% | 1.27B | - | ||
+3.58% | 1.13B | - | ||
+13.51% | 1.12B | C | ||
-2.06% | 1.02B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HARTA Stock
- Ratings Hartalega Holdings